← Back

Wire · opportunities

FDA Clears CPETWise Cardiopulmonary Exercise Testing Software

Published

4 September 2026

Topic

opportunities

Sectors

Health: Diagnostics

Geography

United States

Source

Read at respiratory-therapy.com

Verified

Fusion42 · 4 September 2026 · Fusion42 review

The FDA granted 510(k) clearance to Medibyt’s CPETWise software, allowing commercialization in the US. The platform reduces cardiopulmonary exercise testing interpretation time by over 50% and standardizes clinical workflows while preserving raw data access for clinicians.

This Wire brief sits within Fusion42's coverage of Health: Diagnostics, and 4 sources have reported it between 1 Sep 2026 and 4 Sep 2026.

◆ The Wire takeaway

Medibyt’s FDA clearance opens the US market for automated cardiopulmonary exercise testing software, forcing competitors to accelerate or partner to meet these efficiency gains. You gain a chance to approach large clinical users now onboarding advanced automated workflows.

Coverage

4 sources · first reported 1 Sep 2026 · latest 4 Sep 2026

Related on Wire

Topics

Health: DiagnosticsFDA-clearancedigital-healthcardiopulmonary-testingworkflow-automationclinical-efficiency